The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...

Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European ...

The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines for approval at its ...

On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

The Food and Drug Administration (FDA) has approved Datroway ® (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human ...